Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT-FUL long-term extension of inhaled imatinib for pulmonary arterial hypertension
NL-OMON59787Phase 3Completed
- Sponsor
- Aerovate Therapeutics
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 4-chlorokynurenine in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Primary endpoints: Safety and tolerability of AV-101, Change from baseline in 6-minute walk distance and 3 more. Started Nov 2022; status: completed.
02
Drugs
4-chlorokynurenine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON59787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59787.